A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects

What Was Tested

This randomized controlled trial paper looks at Semaglutide.

Semaglutide is a glucagon-like peptide-1 analogue for once-weekly subcutaneous treatment of type 2 diabetes.

Japanese trial registration number JapicCTI-142550.

Who Took Part

The abstract describes 44 subjects taking part.

The age groups tagged for this paper are young adults, adults and middle-aged adults, men only.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and parallel-group study.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the subjects nor the staff measuring them knew who was on Semaglutide, so expectations could not easily colour the readings.

Some subjects received a placebo instead of Semaglutide, giving a reference point.

The Semaglutide group and the comparison group ran side by side rather than switching.

The primary endpoint was semaglutide exposure at steady state [area under the curve (AUC0-168h)].

What Was Measured

The subject headings attached to it are Area Under Curve, Asian People, Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Glucagon-Like Peptides, Half-Life and Hypoglycemic Agents.

The authors tagged it with the keywords GLP-1 receptor agonist, Japanese subjects, Semaglutide and Type 2 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Semaglutide in 44 subjects.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (Advances in therapy), a journal based in United States.

More context: the Semaglutide compound page.